GSK Strategy Chief: No Major M&A Likely In 2017
Executive Summary
GSK expects further consolidation among rivals in 2017 but its own focus will remain internal, as it keeps integrating assets acquired by its product swap with Novartis and as its new CEO takes corporate control.